What constitutes failure for Helicobacter pylori eradication therapy?

Area of Science:

• Gastroenterology
• Infectious Diseases
• Microbiology

Background:

• Helicobacter pylori eradication therapy is increasingly used beyond peptic ulcer disease, including for H. pylori-positive dyspepsia and gastric cancer risk.
• Standard treatment involves a proton pump inhibitor and two antibiotics for at least one week.

Purpose of the Study:

• To review factors influencing Helicobacter pylori eradication therapy success and failure.
• To highlight the impact of antibiotic resistance and bacterial/host factors on treatment outcomes.

Main Methods:

• Literature review of studies on H. pylori eradication therapy.
• Analysis of factors contributing to treatment failure, including noncompliance and antibiotic resistance patterns.
• Examination of regional variations in antibiotic resistance prevalence.

Main Results:

• Treatment failure is primarily linked to noncompliance and antibiotic resistance, with resistance rates varying significantly by geographic region.
• Nitroimidazole resistance is observed in 7-60% of cases, while macrolide resistance ranges from 1-15%.
• Macrolide resistance is associated with higher treatment failure rates (>50%) compared to nitroimidazole resistance (<50%).

Conclusions:

• Antibiotic resistance is a major challenge in H. pylori eradication, necessitating careful antibiotic selection.
• Bacterial virulence factors and host inflammatory responses also impact eradication success.
• Second-line treatment should avoid antibiotics with potential post-therapeutic resistance and ensure adequate acid suppression.